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Central nervous system (CNS) is an immune privileged site, nevertheless inﬂammation associates with many CNS diseases.
Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear hormone receptors that regulate immune and
inﬂammatory responses. Speciﬁc ligands for PPARα, γ,a n dδ isoforms have proven eﬀective in the animal models of
multiple sclerosis (MS), Alzheimer’s disease, Parkinson’s disease, and trauma/stroke, suggesting their use in the treatment
of neuroinﬂammatory diseases. The activation of NF-κB and Jak-Stat signaling pathways and secretion of inﬂammatory
cytokines are critical in the pathogenesis of CNS diseases. Interestingly, PPAR agonists mitigate CNS disease by modulating
inﬂammatory signaling network in immune cells. In this manuscript, we review the current knowledge on how PPARs regulate
neuroinﬂammatory signaling networks in CNS diseases.
Copyright © 2008 John J. Bright et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
The central nervous system (CNS) was thought to be an
immune privileged site due to the ability of blood-brain-
barrier (BBB) to shield immune cell entry and protect from
the constantly changing circulatory milieu. Nevertheless,
activated immune cells readily traverse the BBB, secrete
inﬂammatory cytokines, and mediate many CNS diseases.
Neuroinﬂammatory diseases present major challenges to
the health care system and impose substantial economic
costs around the world. Current treatments targeting clinical
symptoms of CNS diseases have modest therapeutic values
in patients. Signiﬁcant progress has been made in recent
years in developing therapeutic strategies for the treatment
of neuroinﬂammatory diseases.
2. NEUROINFLAMMATORY DISEASES
The innate and adaptive immunity evoked during infection
in the CNS often leads to the development of neuroinﬂam-
matory diseases [1–3]. The mounting evidence suggests that
neuroinﬂammatory diseases such as multiple sclerosis (MS),
Alzheimer’s disease (AD), trauma, and ischemia/stroke can
occur in the absence of infection. MS is an inﬂammatory
demyelinating disease of the CNS with clinical symptoms
ranging from pain to paralysis and the patients becoming
wheel-chair bound for rest of their lives [4]. Although the
etiology of MS is not known, it is generally viewed as a
neural antigen-speciﬁc T cell-mediated autoimmune disease
[4–6]. Experimental allergic encephalomyelitis (EAE) is an
autoimmune disease model of MS, commonly used to study
the mechanism of disease pathogenesis and to test the
eﬃcacy of potential therapeutic agents for the treatment of
MS. In AD, the deposition of beta-amyloid (Aβ) and plaque
formation in the CNS associate with inﬂammation resulting
in neuronal death, progressive deterioration of cognitive
functions, and memory loss [7, 8]. Traumatic brain injury
(TBI), spinal cord injury, and ischemic stroke also display
neuroinﬂammation associated secondary tissue damage in
the CNS [9, 10]. The pathogenesis of neuroinﬂammatory
diseases involves the orchestrated interaction of immune
cells resulting in tissue injury to the CNS [6, 11]. Although
the exact mechanisms are not known, recent evidence sug-
gests the use of peroxisome proliferator-activated receptor
(PPAR) agonists in the treatment of neuroinﬂammatory
diseases.
3. PPAR ISOFORMS AND THEIR LIGANDS
PPAR is a family of ligand-dependent nuclear hormone
receptor transcription factors that play key roles in the2 PPAR Research
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Figure 1: (a) Functional domains of PPAR isoforms. N, N-terminus; DBD: DNA-binding domain; LBD: ligand-binding domain. The
numbers represent percentage identity to human PPARα. (b) PPAR/RXR binds to PPREDR-1 promoter regions. Binding of agonists leads to
heterodimerization, recruitment of coactivator and transcriptional activation of target genes.
regulation of immune and inﬂammatory responses [12].
Structure-function analyses revealed that PPARs are com-
posed of a DNA-binding domain (DBD) linked to the
C-terminal ligand-binding domain (LBD) by a hinge
region (Figure 1)[ 13, 14]. PPARs stimulate gene expression
through binding to peroxisome-proliferator response ele-
ments (PPREs), present in the promoter regions of the target
genes. In the absence of ligands, the heterodimers physically
associate with corepressors and suppress gene transcription
[14, 15]. Upon ligand binding, the coactivators replace
corepressors and activate gene expression [16, 17]. PPARα,
PPARβ/δ,a n dP P A R γ are three structurally homologous
isotypesfoundinvariousspecieswhichdisplaydistinctphys-
iological and pharmacological functions [18]. The PPARα is
expressed in liver, kidney, intestine, heart, skeletal muscle,
adrenal gland, pancreas, and brain. PPARα is involved
in acetylcholine metabolism, excitatory neurotransmission,
and oxidative stress defense [19]. PPARα also regulates lipid
metabolism and energy homeostasis through its ability to
stimulate the breakdown of fatty acids and cholesterol,
driving gluconeogenesis and reduction in serum triglyceride
levels [19]. While polyunsaturated fatty acids activate all
threeisoformsofPPARswithdiﬀerentaﬃnities,eachisotype
hasitsownligandbindingproperty[20].Fibrates,WY14643,
and GW7647 are PPARα agonists commonly used for the
treatment of hypertriglyceridemia [19].
PPARβ/δ is ubiquitously expressed in all cell types in-
cluding immature oligodendrocytes and promotes diﬀer-
entiation and myelination in the CNS [21–23]. PPARβ/δ
null mice show an altered myelination of corpus callo-
sum, suggesting its role in brain function [24]. PPARβ/δ
regulates transcriptional activation of Acyl-CoA synthetase
2, a key enzyme in fatty acid utilization, suggesting its
role in lipid metabolism in the brain. Prostagladin I2,
GW0742, GW501516, and GW7842 are PPARβ/δ agonists
which induce fatty acid oxidation in muscle [25]. PPARγ
expression is detected in adipose tissue intestinal mucosa,
retina, skeletal muscle, heart, liver, and lymphoid organs
[26]. PPARγ is expressed in microglia and astrocytes and
regulates inﬂammation in the CNS [27, 28]. Eicosanoids
and prostaglandin J2 (15d-PGJ2) are the naturally occurring
PPARγ ligands, and thiazolidinedones (TZDs) including
pioglitazone (Actos) and rosiglitazone (Avandia) are Food
and Drug Administration (FDA) approved synthetic drugs
forthetreatmentoftypeIIdiabetes [29]. Recent studies have
shown the use of PPAR agonists in the treatment of many
neuroinﬂammatory diseases.
4. THERAPEUTIC EFFECTS OF PPAR
AGONISTS IN CNS DISEASES
The therapeutic eﬀects of PPAR agonists have been tested
in many diﬀerent neuroinﬂammatory diseases (Table 1).
The use of PPARγ agonists in the treatment of MS has
been tested in EAE model by diﬀerent groups [30–33]. In
vivo treatment with synthetic PPARγ ligand, troglitazone,
ameliorates EAE by reducing the inﬁltration of leukocytes in
the CNS [34]. Two other studies also showed that in vivo
treatment with PPARγ ligands, 15d-PGJ2 and ciglitazone,
ameliorates EAE [30, 31]. Oral treatment with pioglitazone
inhibits chronic progressive and relapsing forms of EAE even
when administered at the peak of disease [35, 36], suggesting
their use of PPARγ agonists in the treatment of MS. PPARγ-
deﬁcient heterozygous mice develop an exacerbated EAE
withincreasedCNSinﬂammationanddemyelination[37].A
recent report also showed that PPARγ antagonists, bisphenol
A diglycidyl ether (BADGE), and 2-chloro-5 nitro-N-(4
pyridyl) benzamide (T007) reversed the inhibition of EAE
by PPARγ agonists, further suggesting the physiological role
of PPARγ in the pathogenesis of EAE [38].
Epidemiological studies suggest a reduced risk of AD
among the users of nonsteroidal anti-inﬂammatory drugs
(NSAID)[39,40].Treatmentwithpioglitazoneandrosiglita-
zone signiﬁcantly reduced the lesion size, motor neuron loss,
myelin loss, astrogliosis, microglial activation, and chronic
thermal hyperalgesia in spinal cord injury [41]. In a rat
model of AD induced by cortical Aβ injection, ciglitazone
and pioglitazone suppressed the clinical symptoms signiﬁ-
cantly. In the amyloid precursor protein (APP) transgenic
model of AD, treatment with pioglitazone reduced the
plaque burden by aﬀecting the production, clearance, and
homeostasis of Aβ in the CNS [42]. A clinical trial involving
500 AD patients showed signiﬁcant improvement in cogni-
tion following treatment with rosiglitazone for 6 months,
suggesting its use in the treatment of AD [43]. Recent evi-
dencealsosuggeststhatNSAIDssuchasibuprofenmaydelay
or prevent the development of Parkinson’s disease (PD) [44,
45].Moreover,PPARγ isexpressedintheCNSof1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced model
of PD [24] and treatment with pioglitazone protected
the animals from neuronal cell death [46]. Similar resultsJohn J. Bright et al. 3
Table 1: Role of PPARs in the regulation of neuroinﬂammatory diseases.
CNS disease Inﬂammatory response Eﬀect of PPAR agonists
Multiple sclerosis
Activation of macrophage, microglia and dendritic
cells; inﬁltration of Th1/Th17 cells in the CNS;
induction of NF-κB and Jak-Stat pathway and release of
IL-12, IFNγ, IL-17 and other cytokines in the CNS
PPARα, δ and γ agonists
ameliorate EAE by inhibiting
inﬂammation
Alzheimer’s disease
Beta-amyloid (Aβ) accumulation leads to CNS
inﬂammation via TNFα and NF-κB pathway and
secretion of inﬂammatory cytokines
PPARγ ligands reduce neuronal
loss in animal models of AD
Infection
During bacterial, viral, fungal and parasitic infection,
activated APC and T cells release TNFα,I F N γ, iNOS,
IL-2, IL-6 and induce inﬂammation via NF-κB, Stat
and AP-1 signaling pathways
PPAR agonists regulate infection
associated inﬂammation
Trauma
CNS injury results in the activation of resident
microglia and astrocytes resulting inﬂammation
through secretion of TNFα, prostaglandin and COX-2
and mediate inﬂammation via NF-κB, Stat1 and AP-1
pathways
PPARα, δ and γ ligands regulate
inﬂammatory response in
trauma
Ischemia/stroke
Ischemic stroke associates with recruitment and
activation of macrophages and neutrophils via
increased expression of VCAM-1, ICAM-1, IL-6, IL-8
and COX-2 through Stat-1
PPARγ ligands reduce the infarct
size in animal models
were also generated using lipopolysaccharide (LPS)-induced
inﬂammation model of dopaminergic neurodegeneration
in rat, where pioglitazone treatment eﬀectively reduced
inﬂammation, oxidative stress, and restored mitochondrial
function [47]. Treatment with pioglitazone also extends the
survivalofsuperoxidedismutase-1(SOD1-G93A)transgenic
animalmodelofamylotrophiclateralsclerosis(ALS)[36,48–
51].
The eﬀects of PPAR agonists in reducing deleterious
inﬂammatory responses suggest their use in the treatment
of trauma, spinal cord injury, and stroke. Experimental evi-
dence suggests that the Pro12Ala polymorphism of PPARγ2
is associated with a reduced risk for ischemic stroke [52]a n d
treatment with TZDs and 15d-PGJ2 cause neuroprotection
in animal models of stroke. Treatment with PPARγ agonists
also reduce the infarct volumes and improve sensorimotor
function in a rodent model of middle cerebral artery
occlusion (MCAO) [53, 54]. Similar eﬀects were observed
following oral or intracerebrovascular administration of
PPARγ agonists [55, 56]. TZD-unrelated PPARγ agonist L-
796,449 decreases infarct size and improves neurological
scores after MCAO in the rat brain [57]. Treatment with
PPARγ antagonist T0070907 increased the infarct size and
reversed rosiglitazone-induced protection after stroke. A
small clinical trial has revealed improved functional recov-
ery after stroke in diabetic patients receiving pioglitazone
or rosiglitazone compared to patients not receiving TZD
therapy [58]. A recent clinical trial demonstrated that
pioglitazone signiﬁcantly reduced the combined risk of
myocardial infarction and stroke-associated death in high-
risk patients with type 2 diabetes [59].
Recent studies have demonstrated the beneﬁcial eﬀects
of PPARα agonists in the treatment of neuroinﬂammatory
diseases. Oral treatment with gemﬁbrozil protects mice
from EAE [60]. The tyrosine hydroxylase (TH)-positive
SNpc cells express PPARα and in vivo treatment with
PPARα agonist, fenoﬁbrate, protects mice from MPTP-
induced inﬂammation and neuronal loss. In vivo treatment
with PPARα agonist, fenoﬁbrate and WY-14643, reduced
the infarct size in mouse models of stroke [61, 62]. This
eﬀect was absent in PPARα deﬁcient mice, reinforcing
receptor dependency of the observed eﬀects . Treatment
with PPARα agonist, fenoﬁbrate, decreases the neurological
deﬁcit induced by traumatic brain injury (TBI) caused by
lateral ﬂuid percussion of brain in rats [63]. Fenoﬁbrate
also reduces brain edema and ICAM-1 expression and
induces neurological recovery associated with a reduction
of the brain lesion. Anti-inﬂammatory therapies showed
neuroprotective eﬀects after spinal cord injury in rodents
[64, 65]. Moreover, oral treatment with selective PPARβ/δ
agonist GW0742 exerted beneﬁcial eﬀects in the MOGp35-
55-induced EAE model [66]. GW0742 reduced the severity
ofEAEevenwhenadministeredatthepeakofclinicaldisease
[66]. PPAR β/δ null mice exhibit signiﬁcantly greater infarct
sizes than wild type animals suggesting its role in stroke [67].
5. PPAR AGONISTS REGULATE INFLAMMATORY
CYTOKINES IN CNS DISEASES
The anti-inﬂammatory eﬀects of PPARγ agonists have been
extensively studied in CNS diseases (Table 2). While the
inﬂammatory cytokines, IL-1β,I L - 6 ,T N F α, IL-12, IL-23,
IL-27, IFNγ, and IL-17, mediate the pathogenesis of CNS
diseases, anti-inﬂammatory cytokines, IL-4, IFNβ,T G F β,
and IL-10, confer recovery in MS and its animal model,
EAE [68–70]. In EAE model of MS, PPARγ agonists decrease4 PPAR Research
Table 2: Role of PPARs in the regulation of inﬂammatory signaling pathways in CNS diseases.
Tissue Distribution PPAR Agonists Eﬀect and Mode of Action in CNS diseases
PPARα
Expressed in liver, heart, kidney,
large intestine, skeletal muscle and
astrocytes. PPARα knockout mice
develop severe LPS-induced
inﬂammation
Palmitic acid, linoleic acid, stearic
acid, palmitoleic acid, oleic acid,
8-HETE, Wy-14643, cloﬁbrate,
nafenopin, bezaﬁbrate, fenoﬁbrate
PPARα agonists inhibit Aβ induced expression
of TNFα, IL-6, IL-4 and inﬁltration of CD4+ T
cells in the CNS of AD; reduce ICAM-1
expression and oxidative damage in stroke;
protect MPTP-induced loss of neurons in PD;
protect mice from EAE by inhibiting IFNγ,
TNFα and IL-6 production in stroke, cerebral
ischemia and MS models
PPARβ/δ
Expressed ubiquitously in brain,
adipose tissue and skin. PPARβ/δ
knockout mice show reduced fat
deposition
Prostacyclin, PGI2, GW0742,
GW501516, GW7842, L165041
PPARβ/δ agonists reduce the severity of EAE
and stroke by inhibiting NF-κB and Jak-Stat
signaling pathways in immune cells from MS
and stroke models
PPARγ
Expressed in heart, muscle, colon,
kidney, pancreas, spleen,
macrophage, intestine, adipose
t i s s u ea n dl i v e r .P P A R γ knockouts
are embryonically lethal
Prostaglandin J2, thiazolidinediones,
pioglitazone, rosiglitazone, GW78456,
WY14,643, GW7647
PPARγ agonists inhibit T-cell proliferation,
IFNγ, IL-10 and IL-4 production through
blocking NF-κB, AP-1 and Jak-Stat pathways in
CNS diseases models of AD, PD, Trauma, MS,
ALS, stroke and ischemia
the TNFα mRNA expression in antigen-speciﬁc T cell in
vitro [71]. Other studies have shown that 15d-PGJ2 inhibits
EAE in association with inhibition of T-cell proliferation
and secretion of inﬂammatory cytokines including IFNγ,
IL-10, and IL-4 in culture [31–34]. PPARγ agonists, 15d-
PGJ2 and ciglitazone, block IL-12 signaling through Jak-
Stat pathway leading to Th1 diﬀerentiation in T cells.
Pioglitazone also suppresses IFNγ s e c r e t i o ni ns p l e e nT
cells following stimulation with MOGp35-55 in vitro [30].
The activation of resident glial cells and inﬁltration of
leukocytes contribute to demyelination in EAE and MS.
The chemokines and chemokine receptors promote the
traﬃcking and entry of immune cells across blood-brain
barrier into the CNS in EAE and MS [71–74]. Whereas,
PPARγ agonists, troglitazone and pioglitazone, reduce the
expression of MCP1 [33], IP-10 (CXCL3), MIG, I-TAC,
MIP1α, and RANTES [27] that contribute to reduced
inﬁltration of immune cells in the MOG-induced EAE [73,
74]. Moreover, the surface molecules such as MHC class II,
CD40, CD28, and ICAM enhance the disease pathogenesis
and CTLA4 inhibits EAE/MS [75]. Negative regulation of
adhesion molecules may also account for reduced brain
inﬁltration observed in PPARγ agonists treated EAE mice.
The immunomodulatory eﬀects of PPARγ agonists
were tested in human peripheral blood mononuclear cells
(PBMCs). In vitro treatment of cells with pioglitazone, cigli-
tazone, and GW347845 abolished proliferation and cytokine
secretion accompanied by DNA condensation and down-
regulation of bcl-2, suggesting the induction of apoptosis in
activated T lymphocytes. MS patients showed a decrease in
the expression of PPARγ in immune cells and a reduction
in the anti-inﬂammatory eﬀects of pioglitazone when com-
pared to healthy controls [35, 36, 76]. However, treatment
of immune cells derived from diabetic patients with piogli-
tazone in vitro or by oral treatment in vivo increased the
expression and DNA-binding activity of PPARγ [77]. In MS
patients, pioglitazone increased the DNA binding activity of
PPARγ and decreased the NF-κB activity by increasing IκBα.
Activated microglial cells were signiﬁcantly reduced at sites
of neurodegeneration in pioglitazone-treated SOD1-G93A
mice, as were the protein levels of COX-2 and iNOS. The
mRNA levels of the suppressor of cytokine signaling 1 and
3 genes were also increased by pioglitazone [48], but their
functional signiﬁcance is not well known.
In vivo treatment with PPARγ agonists suppresses Aβ-
evoked microglial activation and inﬂammatory cytokine
expression, iNOS expression and NO production, and inhi-
bitionofCOX-2inAβ-evokedanimalmodelsofADandAPP
[42]. PPARγ agonists also suppress Aβ-mediated activation
of microglia in vitro [40–43]. The expression of iNOS in
neurons resulted in neuronal cell death which was prevented
by activation of PPARγ in vitro and in vivo [42, 43].
Neuroinﬂammatory changes accompanied by activation of
microgliaandastrocytesandexpressionofTNFα,IL-1β,and
iNOSplayapivotalroleinPD[46].Anincreaseininﬁltrating
CD8+ T lymphocytes and IFNγ+ cells were also reported
in the CNS with PD. Pioglitazone decreased microglia and
astrocyte activation and reduced the number of iNOS-
positive cells in the CNS [47]. In trauma, macrophages, and
neutrophils are involved in the early stages of inﬂammation
followed by leukocyte recruitment via VCAM-1, ICAM-1,
IL-6, IL-8, and COX-2 [75]. The leukocytes and microglia
mount inﬂammatory responses with elevated expression of
cytokines, chemokines, adhesion molecules, iNOS, COX-
2, and other inﬂammatory mediators that exacerbate the
tissue damage [61]. Treatment with pioglitazone signiﬁ-
cantly reduced the induction of inﬂammatory genes, IL-
1β, IL-6, monocyte chemoatractant protein-1, and intra-
cellular adhesionmolecule-1. The PPARγ antagonist, 2-
chloro-5-nitro-N-phenyl-benzamide (GW9662), preventedJohn J. Bright et al. 5
the neuroprotective eﬀect of pioglitazone [48], suggesting
the involvement of PPARγ-dependent mechanisms in the
regulation of inﬂammation and new therapeutic avenue for
the treatment of MS.
The expression and activation of PPARα in T lympho-
cytes decreases IL-2 production and proliferation. PPARα-
null mice show an augmented LPS-induced inﬂammatory
response and oral treatment with gemﬁbrozil reduced CD4+
lymphocyte and macrophage inﬁltration into the CNS
of mice with EAE. Several agonists of PPARα, including
gemﬁbrozil and ciproﬁbrate, decreased murine lymphocyte
proliferation in a concentration-dependent manner, in vitro
[60]. The gemﬁbrozil and ciproﬁbrate-induced IL-4 pro-
duction in murine and human lymphocytes, whereas IFNγ
production was decreased. WY14,643, a synthetic PPARα
agonist, reduced the IgG response in mice with EAE and
impaired generation of IFNγ,T N F α, and IL-6 in response to
MOG peptide in vitro. PPARα and PPARβ/δ are expressed in
astrocytes, while the latter are present more in oligodendro-
cytes,thusplayingaroleintheprocessofremyelination[66].
In AD, the neuroinﬂammatory components include resident
microglia, astrocyte, the complement system, cytokines, and
chemokines. Microglia and astrocytes generate beta-amyloid
protein that stimulate proinﬂammatory cytokines in AD
brain. PPARα agonists inhibitAβ-stimulated expression of
TNFα and IL-6 in a dose dependent manner [40, 42]. In
trauma and spinal cord injury-induced edema, neutrophil
inﬁltration and immunoreactivity to TNFα were augmented
with a worsened recovery of limb function in PPARα
knockout than wild type mice. CNS injury leads to rapid
recruitment of microglia, macrophage, and astrocytes that
secrete IL-1, TNFα, iNOS, PGs, and COX-2 [63]. Fenoﬁbrate
promotes neurological recovery by decreasing iNOS, COX2,
MMP9 expression, and antioxidant eﬀect in TBI. Although
PPAR agonists inhibit neuroinﬂammation in many CNS
diseases, their modes of action are not well characterized.
6. PPAR AGONISTS REGULATE IL-12 FAMILY
CYTOKINES IN CNS DISEASES
IL-12, IL-23, and IL-27 are three IL-12 family cytokines
produced by macrophage, microglia, and dendritic cells in
the CNS. IL-12 is a 70 kD heterodimeric cytokine composed
of p40 and p35 subunits encoded by two diﬀerent genes
that play a critical role in the diﬀerentiation of neural
antigen-speciﬁc Th1 cells in EAE [78, 79]. We and others
have shown earlier that in vivo treatment with neutralizing
anti-IL-12p40 antibody prevents EAE [79]. Furthermore,
therapeutic intervention of IL-12-signaling was eﬀective in
preventing EAE. We have shown that PPARγ agonists inhibit
IL-12 production, IL-12 signaling, and diﬀerentiation of Th1
cells in EAE [30]. We have also shown that PPARγ-deﬁcient
heterozygous mice develop an exacerbated EAE in associ-
ation with an augmented Th1 response [37], suggesting a
physiological role for PPARγ in the regulation of IL-12/IFNγ
axis in CNS demyelination. IL-23 is a heterodimeric cytokine
composed of a common IL-12p40 subunit and an IL-23p19
subunitspeciﬁctoIL-23encodedbytwodiﬀerentgenes[70].
Signaling through its receptor, composed of IL-12Rβ1a n d
IL-23R,IL-23inducestheactivationofJak-Statpathwaysand
diﬀerentiationofIL-17producing(Th17)cellsfrommemory
Th1 cells, leading to the pathogenesis of EAE [80]. Targeted
disruption of IL-23p19 in mice was eﬀective in preventing
the pathogenesis of EAE [70, 81] and suggested that the
IL-23/IL-17 axis plays a critical role in the pathogenesis of
CNS inﬂammation and demyelination. Although IL-6 and
TGFβ [82] are important mediators of Th17 diﬀerentiation
in culture, their physiological role in activating Th17 cells in
CNS disease is not known (Figure 2).
IL-27 is another heterodimeric cytokine consisting of
E B I 3a n dp 2 8e n c o d e db yt w od i ﬀerent genes. IL-27 receptor
iscomposedofWSX-1andgp130moleculesthatmediateIL-
27-induced activation of the Jak-Stat pathway in naive CD4+
T cells [83]. In vivo treatment with anti-IL-27 antibody
ameliorates EAE, suggesting its role in the pathogenesis of
Th1cell-mediatedautoimmunediseases.Recentstudieshave
also shown that IL-27 and IFNγ are potent inducers of T-
bet, a T-box protein transcription factor, in T cells. Targeted
disruption of T-bet or siRNA inhibition of T-bet was
suﬃcient to prevent the pathogenesis of EAE, suggesting the
critical role of IL-27/IFNγ/T-bet axis in the pathogenesis of
demyelination [84]. PPARγ agonists regulate IL-27/IFNγ/T-
bet axis in EAE. Interestingly, recent studies have shown that
EBI3 can also heterodimerize with IL-12p35 to form IL-35 in
CD4+-Foxp3+ regulatory T cells and functions as a potent
anti-inﬂammatory cytokine [85]. Although PPARγ has been
shown to upregulate Treg cells in vitro [86], the role of PPAR
in the development of Treg cells or production of IL-35 in
EAE/MS or other CNS diseases is not known.
7. PPAR AGONISTS REGULATE NF-κB SIGNALING
PATHWAYS IN CNS DISEASES
The IL-12 family cytokines are produced by macrophage,
microglia, and dendritic cells in response to autoantigens,
TLR ligands, and CD40 ligands [87]. In earlier studies, we
and others have shown that autoimmune cells secrete IL-12
in response to antigens and that this response was inhibited
by treatment with PPARγ agonists [30]. PPARγ agonists also
inhibit LPS and CD40L-induced secretion of IL-12 from
macrophage, microglia, and dendritic cells. The induction
of IL-12/IL-23 gene expression involves activation of the
NF-κB signaling pathway in antigen-presenting cells [88].
NF-κB is a heterodimeric transcription factor composed
of p50 and p65 subunits from the Rel family of proteins.
It is sequestered in the cytoplasm as an inactive complex
when associated with its inhibitor, IκB.Upon stimulation
with speciﬁc inducers, IκB is phosphorylated and degraded
through proteosome-mediated pathways. The activated NF-
κB then translocates into the nucleus and binds to speciﬁc
10 bp response elements of the IL-12, IL-23, and IL-27 genes
[88, 89]A c t i v a t i o no fN F - κB is a complex process involving
the successive action of proximal NF-κB-inducing kinase
(NIK) and the IκB kinases, IKKα,I K K β,a n dI K K γ [90].
The expression of the IL-12 p40 subunit is controlled by
proximal cis-acting elements (NF-κB half site) interacting
with NF-κBf a m i l ym e m b e r s[ 91]. Inhibitors of IL-12 gene
expression, including retinoids, acetyl salicylic acid, and6 PPAR Research
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Figure 2:RegulationofneuroinﬂammationbyPPARagonistsinCNSdiseases.CD40/TLRinducetheactivationofNF-κBpathwayleadingto
expression of IL-12 family cytokines from APCs which in turn signal through Jak-Stat pathway in T cells leading to Th1/Th17 diﬀerentiation
and development of CNS diseases. PPAR agonists modulate signaling and transcription in APC and T cells thereby preventing CNS diseases.
PPAR regulates NF-κB pathway leading to IL-12 family
gene expression in CNS diseases
CpG
MD2
TLR9
MyD88
TRAF
LBP LPS
MD2
TLR4
CD14
TRIF TRAF6
NIK/IKK
I-κB
p
p65
p50
p
IL-12, IL-23, IL-27 gene expression
Th1, Th17 diﬀerentiation
inﬂammation and CNS disease
CD40L
CD40
PPAR agonist
RXR
PPAR
PPAR antagonist
Figure 3: Regulation of NF-κB pathway by PPAR agonists in CNS diseases. The activation of microglia, macrophage and dendritic cells
through toll-like receptor, CD40 or cytokine associated NF-κB pathway leads to secretion of inﬂammatory cytokines leading to pathogenesis
of CNS diseases. PPAR agonists inhibit NF-κB pathway resulting in inhibition of CNS diseases.John J. Bright et al. 7
PPAR regulation of JAK-STAT pathway induced by IL-12 family cytokines in CNS diseases
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Figure 4: IL-12, IL-23 and IL-27 are heterodimeric cytokines signals through Jak-Stat pathway and induce Th1/Th17 diﬀerentiation and
T-bet expression in T cells. Treatment with PPAR agonists regulate these responses in T cells resulting in inhibition of CNS inﬂammation.
1,25 dihydroxyvitamin D3, block NF-κB activation and bind
within the IL-12p40 promoter [92, 93]. The inhibition of
NF-κB pathway leading to the expression of IL-12 family
cytokines by PPAR agonists suggests this be a mechanism by
which PPAR agonists regulate CNS diseases (Figure 3).
The NF-κB family of proteins (RelA/p65, RelB, c-Rel,
p50, p52) are widely expressed in the CNS [94]a n da c t i v a t e d
in a number of CNS inﬂammatory diseases. Microglia plays
a pivotal role in immune surveillance and host defense
against infectious agents in the CNS. NF-κB, JNK, and p38
pathways are responsible for F-actin architecture during
microglial activation. In AD, NF-κB activation is increased
when compared to control brain. The brain samples from
PD patients showed an increased nuclear p65 (RelA) in
dopaminergic neurons when compared to age matched
controls [95]. The spinal cord samples from ALS patients
with degenerating motor neurons showed increased NF-
κB activation in astrocytes that are controlled by c-jun,
and JNK/SAPK kinases [96]. In MS patients, NF-κBa n d
c-jun activities are increased in chronic lesions. PPARs are
expressed in microglial cells and PPARγ agonists act as
negative regulators for elements that contain Stat binding
sites. While the inﬂammatory cascade is mediated via both
NF-κB and JNK pathways,PPARγ agonists increase the levels
of IκB-α and IκB-β and reduce the nuclear translocation
of NF-κB[ 97]. While the induction of NF-κBp r o m o t e s
postischemic inﬂammation, PPAR agonists prevent postis-
chemic inﬂammation and neuronal damage by inhibiting
NF-κB pathway. Further analyses indicate that L-796,449
inhibits NF-κB signaling through both PPARγ-dependent
and independent pathways. In addition, spinal cord injury
(SCI) associated neuronal damage was less severe in NF-κB
knockout mice. PPARγ induces transrepression of NF-κB-
induced inﬂammatory genes through their association with
corepressor complexes [96].
8. PPAR AGONISTS REGULATE JAK-STAT SIGNALING
PATHWAY IN CNS DISEASES
The orchestrated interaction of APCs and T cells in the CNS
leads to activation of Jak-Stat signaling pathway, secretion
of inﬂammatory cytokines, and pathogenesis of neuroin-
ﬂammatory diseases. The antigen-induced proliferation of
T cells is a two-step process in which signaling through
T cell receptor (signal 1) drives T cells from resting G0
to activated G1 phase of the cell cycle, whereas signaling
throughIL-2orIL-12receptor(secondsignal)isrequiredfor
T cells to transit from G1 to S/G2/M phase of the cell cycle
(proliferation). IL-12 is a potent inducer of G1 to S/G2/M
phase transition and diﬀerentiation of Th1 cells that are
critical in the pathogenesis of EAE and other CNS diseases.
IL-12 signals through IL-12 receptor β1a n dβ2, members
of the gp130 cytokine receptor super-family, expressed
primarily on activated NK cells and T cells. Coexpression of
IL-12Rβ1andβ2leads tothe formationof highaﬃnity IL-12
receptors [87]. Signaling through its receptor, IL-12 induces
tyrosine phosphorylation and activation of Jak2, Tyk2, Stat3,
and Stat4 in T and NK cells [98, 99]. Activation of the Jak-
Stat pathway leads to transcription of IL-12 response genes
associated with proliferation, Th1 diﬀerentiation, and IFNγ
production. IL-23 receptor is composed of common IL-
12Rβ1 and a speciﬁc IL-23 receptor subunit [100]. Signaling
through its receptor, IL-23 induces the activation of Jak2,
Tyk2, Stat1, Stat3, Stat4, and Stat5 in T cells [98]. Activation
of the Jak-Stat pathway leads to transcription of IL-23
response genes, including IL-17, which are associated with
proliferation of memory T cells [101], whereas IL-27 and
IFNγ activate a speciﬁc Jak-Stat pathway in T cells, resulting
in the induction of T-bet in naive T cells [102]. Modulation
of cytokine signaling by targeting protein tyrosine kinases
or transcription factors has been considered a novel strategy8 PPAR Research
for the treatment of autoimmune diseases [103, 104]. We
have shown earlier that the blockade of IL-12 signaling
throughJak-StatpathwaybytreatmentwithaJak-2inhibitor,
tyrphostin AG490, quercetin, vitamin D, and curcumin
inhibits Th1 diﬀerentiation and pathogenesis of EAE [105–
108]. We have also shown recently that PPARγ agonists
inhibit IL-12-induced tyrosine phosphorylation of Jak2,
Tyk2, Stat3, and Stat4 in T cells, diﬀerentiation of Th1 cells
and pathogenesis of EAE [30]. These ﬁndings suggest that
IL-12 signaling through the Jak-Stat pathway is a molecular
target in the regulation of autoimmune diseases. Recent
studies have shown that the transcription factors such as
Stat4 and T-bet are involved in the pathogenesis of EAE/MS,
whereas Stat6 mediates recovery. While the induction of
Stat1 and Stat3 promotes postischemic inﬂammation, and
Stat-1 knockout mice develop less severe stroke lesions in
the CNS [32], activation of PPARs prevents postischemic
inﬂammation and neuronal damage (Figure 4).
The exact mechanism by which PPAR agonists negatively
regulate neuroinﬂammation, and in particular, the Jak-Stat
signaling pathway is not known. Suppressor of cytokine
signaling (SOCS) proteins are negative regulators of Jak-
Stat pathway. While PPARγ agonists inhibit Jak-Stat pathway
in astrocytes and microglial cells, they rapidly induce the
expression of SOCS 1 and 3, which in turn inhibit Jak
activity in glial cells [109]. In addition, PPAR agonist can
modulate Jak-Stat pathway through activation of Src homol-
ogy 2 domain-containing protein phosphatase 2 (SHP2)
in immune cells, thereby inhibiting neuroinﬂammatory
diseases.
9. CONCLUSION
The neuroinﬂammatory diseases such as multiple sclerosis,
Alzhimer’s disease, stroke, and trauma are common health
problems aﬀecting more than ﬁve percent of the population
worldwide. While the exact mechanisms are not known,
the immune cell activation and secretion of inﬂammatory
cytokines, involving NF-κB and Jak-Stat signaling pathways,
play critical roles in the pathogenesis of many CNS diseases.
Thus, interfering with the signaling network could be
an eﬀective approach in the treatment of MS and other
neuroinﬂammatory diseases. PPAR is a family of nuclear
receptor transcription factors that regulate CNS diseases
by modulating neuroinﬂammatory signaling network. Since
PPAR agonists are already in human use, they are likely to
prove useful in the treatment of MS and other neuroinﬂam-
matory diseases in the near future.
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